BR0108213A - Compostos de cahalalida - Google Patents

Compostos de cahalalida

Info

Publication number
BR0108213A
BR0108213A BR0108213-2A BR0108213A BR0108213A BR 0108213 A BR0108213 A BR 0108213A BR 0108213 A BR0108213 A BR 0108213A BR 0108213 A BR0108213 A BR 0108213A
Authority
BR
Brazil
Prior art keywords
cahalalide
compounds
cahalalid
leads
preparing
Prior art date
Application number
BR0108213-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Fernando Albericio
Ernest Giralt
Jose Carlos Jimenez
Angel Lopez
Ignacio Manzanares
Ignacio Rodriguez
Miriam Royo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0108213A publication Critical patent/BR0108213A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
BR0108213-2A 2000-02-09 2001-02-09 Compostos de cahalalida BR0108213A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
PCT/GB2001/000576 WO2001058934A2 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds

Publications (1)

Publication Number Publication Date
BR0108213A true BR0108213A (pt) 2003-03-05

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108213-2A BR0108213A (pt) 2000-02-09 2001-02-09 Compostos de cahalalida

Country Status (27)

Country Link
US (2) US7482429B2 (https=)
EP (3) EP1829889A3 (https=)
JP (1) JP5188665B2 (https=)
KR (1) KR100871489B1 (https=)
CN (2) CN101597326B (https=)
AT (1) ATE371667T1 (https=)
AU (1) AU783542B2 (https=)
BG (1) BG65926B1 (https=)
BR (1) BR0108213A (https=)
CA (1) CA2399187C (https=)
CY (1) CY1106992T1 (https=)
CZ (1) CZ304258B6 (https=)
DE (1) DE60130192T2 (https=)
DK (1) DK1254162T3 (https=)
ES (1) ES2292558T3 (https=)
GB (1) GB0002952D0 (https=)
HU (1) HUP0301817A3 (https=)
IL (2) IL150981A0 (https=)
MX (1) MXPA02007760A (https=)
NO (1) NO331847B1 (https=)
NZ (1) NZ520488A (https=)
PL (1) PL207121B1 (https=)
PT (1) PT1254162E (https=)
RU (1) RU2280039C2 (https=)
SK (1) SK11242002A3 (https=)
UA (1) UA76949C2 (https=)
WO (1) WO2001058934A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
IL314441A (en) 2022-04-21 2024-09-01 Zevra Therapeutics Inc Gamma-Hydroxybutyrate providing compounds and processes for their production and use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
CA2100745C (en) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7476198A (en) * 1997-05-09 1998-11-27 General Hospital Corporation, The Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7056502B2 (en) * 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
CN101597326B (zh) 2014-07-09
US7482429B2 (en) 2009-01-27
DE60130192D1 (de) 2007-10-11
RU2280039C2 (ru) 2006-07-20
IL150981A (en) 2013-05-30
UA76949C2 (en) 2006-10-16
IL150981A0 (en) 2003-02-12
SK11242002A3 (sk) 2003-06-03
AU3208601A (en) 2001-08-20
PL356800A1 (en) 2004-07-12
EP1254162A2 (en) 2002-11-06
KR100871489B1 (ko) 2008-12-05
JP5188665B2 (ja) 2013-04-24
PT1254162E (pt) 2007-12-03
BG65926B1 (bg) 2010-05-31
CN1422278A (zh) 2003-06-04
MXPA02007760A (es) 2002-10-23
JP2003522198A (ja) 2003-07-22
EP1829889A3 (en) 2007-09-26
CN101597326A (zh) 2009-12-09
NZ520488A (en) 2005-03-24
ATE371667T1 (de) 2007-09-15
HK1047290A1 (en) 2003-02-14
NO20023749D0 (no) 2002-08-08
KR20020092951A (ko) 2002-12-12
AU783542B2 (en) 2005-11-10
CY1106992T1 (el) 2012-09-26
US20040214755A1 (en) 2004-10-28
CZ20022740A3 (cs) 2003-01-15
GB0002952D0 (en) 2000-03-29
EP1829889A2 (en) 2007-09-05
BG107020A (bg) 2003-05-30
DE60130192T2 (de) 2008-05-21
PL207121B1 (pl) 2010-11-30
RU2002123877A (ru) 2004-01-10
ES2292558T3 (es) 2008-03-16
US20080318849A1 (en) 2008-12-25
DK1254162T3 (da) 2008-01-02
CA2399187C (en) 2011-04-19
EP2258715A1 (en) 2010-12-08
NO331847B1 (no) 2012-04-23
WO2001058934A3 (en) 2002-03-21
CA2399187A1 (en) 2001-08-16
CZ304258B6 (cs) 2014-02-05
HUP0301817A3 (en) 2011-10-28
WO2001058934A2 (en) 2001-08-16
HUP0301817A2 (hu) 2003-09-29
NO20023749L (no) 2002-10-07
EP1254162B1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
BR0108213A (pt) Compostos de cahalalida
BR9712285A (pt) Tetrafosfonato bicìclico de trianidridas
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
BR9610129A (pt) Processo para preparação de compostos alifáticos fluorados
BR9812837A (pt) Processo para fazer um composto, e, composto
ECSP034600A (es) Compuestos de lactama
BR9907230B1 (pt) processo para a preparaÇço de um macrâmero.
BR9815441B1 (pt) processo aperfeiçoado para decomposição de um hidroperóxido.
BR9808874B1 (pt) processo para a preparação de um estabilizador com formação de pó reduzida.
PT1230247E (pt) Processo para a estabilizacao de compostos de siloxano
BR9806786B1 (pt) processo para a preparaÇço de um Éter de mono-fléor-metila.
ES2183340T3 (es) Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo.
BR9808923A (pt) Composto, e, processo para fazer o mesmo
BR0204620B1 (pt) processo para o tratamento de condensados que contÊm compostos.
BR9915868A (pt) Processo para a decomposição de tramadol
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
BR9811643A (pt) Suplementação quìmica de osso
BR0113737A (pt) Receptor do domìnio da edbfibronectina (11)
BR9808642A (pt) Processo para preparar eprosartan
BR0110549A (pt) Processo para a preparação de sais de metais alcalino-terrosos do ácido d-pantotênico
BR0009453A (pt) Processo para a preparação de um composto
BR9808664A (pt) Processo para preparar eprosartan
BR9807265A (pt) Processo de epoxidação seletiva para preparação de compostos farmacêuticos
BR0209842A (pt) Processo para a preparação de imipenem
BR9916382A (pt) Processo para a preparação de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2448 DE 05-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.